12:00 AM
Apr 26, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Joulferon albinterferon alfa-2b regulatory update

Novartis withdrew an MAA for Joulferon albinterferon alfa-2b to treat chronic HCV after the European Medicines Agency (EMA) requested additional data that will require the pharma to conduct further studies....

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >